Genetic Technologies Clings to $276K Cash Amid DOCA Restructuring Uncertainty

Background and Administration Status

Genetic Technologies Limited (ASX:GTG), a biotechnology company, continues to operate under voluntary administration following its entry into administration in November 2024. The company’s creditors approved a Deed of Company Arrangement (DOCA) in February 2025, which was formally executed in March 2025. Since then, the appointed administrators from FTI Consulting, Ross Blakeley and Paul Harlond, have been managing the company’s affairs and overseeing restructuring efforts.

Financial Position and Cash Flow

During the quarter ended 30 September 2025, Genetic Technologies did not engage in any trading activities. The company reported a cash balance of $0.276 million, a slight decrease from the previous quarter’s $0.277 million. Operating cash outflows were minimal, primarily covering residual administration and corporate expenses amounting to approximately $2,000. There were no cash inflows from customers or other operating activities during this period.

Governance and Related Party Transactions

Importantly, the company disclosed no payments to related parties or their associates during the quarter, adhering to ASX Listing Rule 4.7C.3. This transparency is crucial given the company’s current administration status and ongoing restructuring process.

Outlook and Uncertainties

While the DOCA administrators continue to manage the company’s restructuring, the filing does not provide details on the timeline or specific plans for resuming operations or raising additional capital. The minimal cash reserves and absence of trading activity underscore the precarious position Genetic Technologies currently occupies. Investors and stakeholders remain in a holding pattern, awaiting further clarity on the company’s strategic direction and financial viability.